Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million Phase Four unveils game changing engine for LEO Constellations Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958 Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735